Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maackiain SCHEMBL12810278 | 1.00 | MAOA (1.00) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Maackiain SCHEMBL29670858 | 1.00 | MAOA (1.00) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Demethylmedicarpin SCHEMBL29843376 | 0.88 | MAOA (0.78) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Medicarpin SCHEMBL2812444 | 0.88 | MAOA (0.78) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Demethylmedicarpin SCHEMBL31663447 | 0.88 | MAOA (0.78) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL8223903 | 0.83 | MAOA (0.71) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL12891393 | 0.83 | MAOA (0.71) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL12810804 | 0.83 | MAOA (0.71) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL232991 | 0.81 | CYP3A4 (0.68) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL19999737 | 0.81 | MAOA (0.67) | MAOAMAOBCYP3A4MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250263774-A1 | DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD | UNIV NORTH TEXAS (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250169516-A1 | METHODS, DEVICES AND COMPOSITIONS FOR PRESERVING HUMAN MILK | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| US-12239142-B2 | Methods, devices and compositions for preserving human milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4499222-A2 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH | Locus Solutions IPCO, LLC (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240366488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2024-11-07 | — | — | US | disclosed |
| US-20240268402-A1 | Methods, Devices and Compositions for Preserving Human Milk | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-08-15 | — | — | US | disclosed |
| CN-117517550-A | Chemical component detection method for expanded roots and non-expanded roots of millettia speciosa champ | 中国热带农业科学院热带作物品种资源研究所 | 2024-02-06 | — | — | CN | disclosed |
| CN-117059172-A | Method for analyzing action mechanism of ginseng for improving erection dysfunction | 广州康兮乐健康科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116492330-A | Application of flavonoid compound in preparation of drug-resistant plasmid conjugation transfer inhibition drug | 扬州大学 | 2023-07-28 | — | — | CN | disclosed |
| CN-107880063-B | Method for synthesizing subprostrate sophora | 浙江工业大学 | 2019-05-28 | — | — | CN | disclosed |
| CN-107880063-A | method for synthesizing subprostrate sophora | 浙江工业大学 | 2018-04-06 | — | — | CN | disclosed |
| CN-106728297-A | Treat pharmaceutical composition of vaginitis and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-106668239-A | Pharmaceutical composition for preventing vitreous opacity | 济南昊雨青田医药技术有限公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-106539928-A | One kind treats rheumatismal pharmaceutical composition and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-106138175-A | The pharmaceutical composition for the treatment of Advanced Colon Cancer | 济南星懿医药技术有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-106109551-A | A kind of pharmaceutical composition preventing and treating chloasma | 济南星懿医药技术有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-105596749-A | Pharmaceutical composition for treating depression and preparing method thereof | JINAN XINGYI MED TECH CO LTD | 2016-05-25 | — | — | CN | disclosed |
| CN-105535060-A | Medicine composition for preventing and treating coronary heart disease | JINAN XINGYI MED TECH CO LTD | 2016-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12507703-B2 | Methods, devices and compositions for preserving human milk | LPL, CEL, LPO | MAOA 471/4885MAOB 293/4885CYP3A4 1678/4885 |
| US-20240366488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HAIR GROWTH | NGF, FGF1, NTRK2 | MAOA 236/4885MAOB 253/4885CYP3A4 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.